Evidence Hub

Drug Repurposing of Metformin as a γ-Secretase Modulator in Cancer therapy

Harshit Narang, Neetu Kukreja Wadhwa, Padmshree Mudgal, Soma Mondal Ghorai

Vantage Journal of Thematic Analysis, 2026

Abstract

A computational approach(in-silico) combined with molecular docking, binding analysis, and interaction profiling was done to evaluate metformin’s affinity for the γ-secretase complex. Known γ-secretase binders—including Avagacestat, Semagacestat, Nirogacestat, RO4929097, and CD147—were used as positive controls for the comparative study and analysis of docking parameters. Metformin demonstrated a favourable binding affinity despite its small size and hydrophilic nature, forming 2 stable hydrogen bonds with critical residues in the receptor’s binding pocket. Comparison with established binders showed overlapping interaction sites, suggesting that metformin could influence γ-secretase activity directly or indirectly. Assessment of hydrogen bonding and atomic contact scores further confirmed the stability and specificity of these interactions. This study highlights metformin as a promising candidate for repurposing as an anticancer agent, potentially targeting both γ-secretase–Notch signaling and cancer metabolism. While the computational results provide strong preliminary evidence, further experimental validation in cell and animal models(in-vitro) is necessary to confirm the biological significance of these interactions. This work demonstrates the value of integrating computational and mechanistic approaches to identify new applications for existing drugs in cancer therapy.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free